As frustrating as the moving of goal posts is, the outlook...

As frustrating as the moving of goal posts is, the outlook remains incredibly positive for Q4 including;
US dental distribution - that is a lock!
Nerve FDA strategy update - also a lock in some form.
ATI final results. one can but hope there is no more slippage.
The fact we now have two very positive announcements in advance of the J&J outcome sees us trading significantly higher before we either go to the moon with J&J as a yes or come back, but off a much higher base if it fails to crystallise (noting that there is more fish in the sea to close an ATI deal with if this is the case).
I agree more management focus should be put on getting analyst coverage, Insto support and better IR, so slippage in results like this is better explained/avoided.